Description
(AWP Alliance News) - Basilea Pharmaceutica reported H1 2026 revenue up 14.4% to CHF 119 million, lifting operating profit 31.7% to CHF 31.6 million. Net profit rose 76.6% to CHF 27.9 million, with diluted EPS of CHF 2.13. R&D spending climbed to CHF 54 million as the company advanced two Phase 3 Fosmanogepix studies and prepared a planned Phase 3 program for Ceftibuten-Ledaborbactam.
Basilea raised its 2026 guidance, now forecasting operating profit growth of about 40% and revenue growth of about 15%. It said the Phase 3 Fosmanogepix program remains on track for data readout and a filing in 2028.
https://www.globenewswire.com/NewsRoom/ReleaseNg/402488867
Disclaimer: This news brief was created using generative artificial intelligence. Basilea Pharmaceutica AG published the original content used to generate this news brief via GlobeNewswire on August 18, 2026, and is solely responsible for the information contained therein.
